New Products Posted to GenomeWeb: Precipio, Seq2Know, Stratify Genomics

Oct 05, 2018

|

Precipio HemeScreen

Precipio has commercially launched HemeScreen, a test for mutations in hematologic cancers. The test measures for mutations in the CALR, JAK2, and MPL genes, as well as in exon 12 of JAK2, all of which are critically important to developing a clinical roadmap for the patient, Precipio said. The company will offer the assay through its CLIA laboratory in New Haven, Connecticut, and will also offer a set of RUO reagents to other reference labs to perform the test in their CLIA laboratories.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Another Look

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

Some More Than Others

A new analysis finds some cancers receive more nonprofit dollars than others.

Gene Variant's Possible Role

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

Science Finds Sex-Biased Gene Expression in Mammals, More

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.

Menu